Targacept announced preliminary results showing that AZD3480 (TC-1734) met the primary outcome measure in a Phase 2 study in adults with attention deficit/hyperactivity disorder (ADHD). The results came from a double blind, placebo controlled, crossover study of patients between 18-65 years of age diagnosed with ADHD based on DSM-IV criteria and had a baseline score of at least 4 on the Clinical Global Impression – Severity scale. At 50mg AZD3480, subjects showed statistically significant (p < .01) improvement in symptoms of ADHD as measured by the study’s primary outcome measure, total symptom score on the Conners Adult ADHD Rating Scale – Investigator Rating (CAARS-INV). Statistically significant results were also achieved at 50mg AZD3480 on a number of secondary outcome measures in the study, including Stop Signal Reaction Time, a computerized assessment of behavioral inhibition, which is a core cognitive deficit of ADHD.
For more information call (336) 480-2100 or visit www.targacept.com.